A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Trial Profile

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top